ABSTRACT During the first 3/2 years of the Stanford heart-lung transplant program, 23 transplants have been carried out in 22 patients with severe pulmonary vascular disease. Actuarial survival curves predict 1 and 2 year survival rates of 71% and 57%, respectively, for all patients. As a result of increasing experience, the early mortality of 26% has been reduced, with only one early death occurring in the last eight patients; prior cardiac surgery was a contributing factor in three of the six patients suffering early deaths. Two late deaths occurred in the series 14 and 15 months after operation. One patient died suddenly as a result of an acute myocardial infarct and the other patient died because of respiratory failure. At autopsy, both patients had severe proliferative coronary atherosclerosis with obliterative bronchiolitis affecting the lungs. An additional patient required a retransplant for obliterative bronchiolitis 37 months after the initial procedure, and he too was found to have severe coronary artery disease. Hemodynamics and left ventricular function were normal in patients studied 1 and 2 years after undergoing the transplantation procedure. Thus, the early mortality and morbidity of combined heart and lung transplantation has been significantly reduced, but the long-term complications, particularly graft atherosclerosis and obliterative bronchiolitis, are yet to be fully controlled.
AFTER 20 years of laboratory experience with combined heart and lung transplantation,' the clinical heart-lung transplant program commenced at Stanford in 1981. Combined heart and lung transplantation in man appeared feasible after the long-term success of heart-lung transplantation in a primate preparation2; the development of cyclosporine as an immunosuppressive agent3 and the experience derived from our cardiac transplant program, in which more than 350 patients have now been treated, were other important factors making such a clinical program appear feasible. Furthermore, the results of simple lung transplan-complications in patients studied 1 to 3½1/ years after operation.
Patients and methods
Between March 1981 and October 1984. 22 patients underwent combined heart and lung transplantation at Stanford University Medical Center (table 1) .
All patients had severe pulmonary vascular disease that was a consequence of primary pulmonary hypertension in 10 patients and congenital heart disease with Eisenmenger's syndrome in 12 patients. In the group with primary pulmonary hypertension two patients were found to have a patent foramen ovale at the time of the transplantation procedure. In the group with congenital heart disease a ventricular septal defect was the most common defect (10 patients), an atrial septal defect was present in four patients, two patients had transposition of the great arteries (L-transposition in one), one patient had a univentricular heart (right ventricular type), and one patient had an aortopulmonary window. One patient had the skeletal abnormalities of the Holt-Oram syndrome.
Three patients had undergone previous cardiac surgery; one had had a persistent ductus arteriosus ligated, one had undergone a Baffes operation7 followed by a palliative Mustard procedure for transposition of the great arteries, and the remaining patient had undergone closure of a ventricular septal defect 18 years before receiving the heart-lung transplant. Two patients had had open lung biopsies. One patient underwent a successful retransplantation procedure 37 months after the initial operation. Five patients were restudied 2 years after transplantation and no significant changes in hemodynamics were noted. In particular, the mean pulmonary arterial pressure for this subgroup (7 ± 2 mm Hg) was similar to that at the first annual study (figure 4).
One patient (No. 2) was restudied 3 years after undergoing the transplantation procedure, at which time his pulmonary arterial pressure had increased significantly since the second annual study (pulmonary arterial pressure 10/0, mean 4 mm Hg, to 30/20, mean 25 mm Hg) (figure 4). His pulmonary vascular resistance had also increased from 0.4 to 1. Conversely, the magnitude of the transplantation procedure is such that the patient with pulmonary hypertension complicated by severe hepatic and renal dysfunction may be too weak to survive the operation and the rigorous early postoperative period if surgery is unduly delayed. In addition, the chronic shortage of suitable donors complicates the optimum timing of surgery still further.
This report documents for the first time that longterm survival (up to 31/2 years) has been achieved in selected patients after combined heart and lung transplantation. Moreover, pulmonary arterial pressure, pulmonary vascular resistance, cardiac output, and left ventricular function were normal in these patients 1 year after the procedure, and in the subgroup of patients restudied 2 years after transplantation hemodynamics had not changed significantly from those at the initial postoperative study. Only one patient (No. 2) developed an increase in pulmonary arterial pressure and pulmonary vascular resistance with time and he eventually required a retransplant 3 years after the first procedure (see below).
The observation of an extensive network of collateral vessels arising from the donor coronary arteries and passing to the region of the tracheal anastomosis has also been observed in primates after heart-lung autotransplantation and allotransplantation,'6 and the provision of an adequate blood supply to this area is presumed to be fundamental to the absence of complications associated with the tracheal suture line in this series of patients, in contrast to the case in the patients reported earlier who had undergone lung transplantation only. 4 Systemic hypertension, a well-recognized consequence of cyclosporine therapy, occurred in all patients and was reasonably well controlled with a conventional regimen of diuretics and vasodilators. Similarly, cyclosporine nephrotoxicity '7 was universal.
The diffuse, distal and concentric nature of graft atherosclerosis'' makes recognition by coronary arteriography difficult. Unless branch arteries are occluded by disease or "missing" compared with the results of a previous study the presence or severity of the condition may be missed or underestimated. This is exemplified in figure 5 : This patient had apparently normal coronary arteries 12 months after the transplantation procedure, but severe diffuse graft atherosclerosis was revealed at postmortem examination 3 months later; it seems unlikely that coronary disease of this severity would have arisen de novo during this 3 month interval. Proliferative coronary atherosclerosis is an important cause of late sudden death and was responsible for one of the two late deaths in this series. Although the exact mechanism of this process is unclear, it seems likely that immune-mediated vascular injury results from chronic low-grade rejection that is inadequately controlled by the presently used maintenance immunosuppressive protocol of cyclosporine and low-dose steroids. Retransplantation of the heart is routinely performed for this complication in the clinical cardiac transplantation program. Theoretically, retransplantation of the heart in a heart-lung transplant recipient would be technically feasible and a reasonable approach in the patient with diffuse cardiac graft atherosclerosis; we have not applied this technique to heartlung recipients as yet because concomitant pulmonary disease was present in all recipients who developed graft atherosclerosis.
Whereas proliferative atherosclerosis is the major complication affecting the grafted heart, the long-term pulmonary sequelae of heart-lung transplantation include airflow obstruction secondary to obliterative bronchiolitis, recurrent respiratory infection, bronchiectasis, and pulmonary fibrosis, all of which have been reported in detail elsewhere. 18 19 Despite the development of these pulmonary complications in a subgroup of the long-term survivors, static lung function20 and objective exercise tolerance2' have been adequate to allow a normal lifestyle in the remainder of patients.
Values for arterial blood gases were within the normal range 1 year after the transplantation procedure, although the alveolar-arterial gradient (a sensitive index of the efficiency of gas exchange) was increased. Sequential estimations of the gradient may prove to be a simple method of monitoring pulmonary function in these patients, thus identifying the need for further investigation. Reoperation was uneventful apart from the presence of dense adhesions that made removal of the recipient organs difficult. Histology of the lungs revealed severe obliterative bronchiolitis and intimal proliferation was apparent in the small pulmonary arterioles. In the heart diffuse graft atherosclerosis was seen throughout the arterial tree.
The histologic similarity between the disease of the coronary and pulmonary vessels in these patients suggests that the causes may be similar. Such changes have been identified in primates 4 to 5 years after heart-lung allotransplantation, but were absent in the long-term survivors of heart-lung autotransplantation. 5 The identification of obliterative bronchiolitis as early as 14 months after transplantation is a major cause for concern, particularly since the response to treatment is unpredictable. Abnormalities of mucociliary transport, an inability to clear foreign antigens, chronic infection, pulmonary rejection, and cyclosporine toxicity may all be involved in the development of obliterative bronchiolitis, but at present the exact cause is a matter of speculation.
Early experience suggested that cardiac and pulmonary rejection occurred pari passu,22 but recent data in animals has demonstrated that rejection of the lung may be observed without concomitant rejection of the heart,23 thus reducing the usefulness of endomyocardial biopsy as an indirect method of pulmonary surveillance. It seems likely that lung biopsy will have to be undertaken more readily in the absence of any noninvasive method of detecting pulmonary rejection.
In conclusion, heart-lung transplantation is a treatment option for patients with terminal pulmonary vascular disease. After the transplantation procedure, hemodynamics at 1 and 2 years are normal, gas exchange at rest is near normal, and functional improvement is excellent. Modifications in the operative technique have led to a reduction in perioperative mortality and morbidity, but long-term complications, particularly proliferative coronary atherosclerosis and obliterative bronchiolitis, have yet to be overcome.
